News & Updates

Bedside genotype testing for mutations in the CYP2C19 gene helps select a better P2Y12 inhibitor treatment strategy for patients with ST-segment elevation myocardial infarction (STEMI) and leads to better outcomes relative to conventional therapy, a recent study has found.

Use of sodium glucose co-transporter 2 inhibitors (SGLT2is) either alone or in combination with dipeptidyl peptidase 4 inhibitors (DPP4is) reduces the risk of hospitalization from heart failure (HHF), a study has shown. In contrast, thiazolidinediones alone or in combination with DPP4is increases HHF risk, but glucose-lowering can help reduce HHF.

Primary percutaneous coronary intervention (pPCI) is as good as conservative management in terms of the benefit for in-hospital mortality among ST-segment elevation myocardial infarction (STEMI) patients receiving maintenance dialysis, a study has found.

A 12-week nurse-led e-health cardiac rehabilitation (NeCR) programme run on a website and a social media chat room effectively modifies behavioural risk factors and improves health-related quality of life (HRQoL) in Chinese patients hospitalized for coronary heart disease (CHD), researchers from the Hong Kong Polytechnic University and the University of Hong Kong have reported.

Cancer patients receiving either low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) show comparable frequency of venous thromboembolism (VTE), reports a recent study.